A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia.

Trial Profile

A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2014

At a glance

  • Drugs Anacetrapib (Primary) ; Atorvastatin
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 27 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Mar 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jul 2010 to 1 Jun 2014.
    • 21 Mar 2014 According to the ClinicalTrials.gov record, status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top